Boston Trust Walden Corp Has $56.82 Million Holdings in Teleflex Incorporated (NYSE:TFX)

Boston Trust Walden Corp increased its stake in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 17.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 227,888 shares of the medical technology company's stock after acquiring an additional 34,100 shares during the period. Boston Trust Walden Corp owned 0.48% of Teleflex worth $56,822,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in TFX. Allworth Financial LP grew its holdings in Teleflex by 332.3% during the third quarter. Allworth Financial LP now owns 134 shares of the medical technology company's stock valued at $26,000 after purchasing an additional 103 shares during the last quarter. Venturi Wealth Management LLC bought a new position in Teleflex in the 3rd quarter worth $27,000. Covestor Ltd lifted its position in Teleflex by 305.6% during the 3rd quarter. Covestor Ltd now owns 146 shares of the medical technology company's stock worth $29,000 after acquiring an additional 110 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in Teleflex by 418.5% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 140 shares of the medical technology company's stock valued at $35,000 after acquiring an additional 113 shares during the period. Finally, ING Groep NV acquired a new stake in shares of Teleflex in the third quarter valued at about $39,000. 95.62% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, VP Cameron P. Hicks sold 7,401 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the transaction, the vice president now directly owns 10,050 shares in the company, valued at $2,261,250. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 1.41% of the company's stock.

Teleflex Price Performance

TFX traded down $2.85 during midday trading on Thursday, reaching $211.89. 333,000 shares of the company's stock were exchanged, compared to its average volume of 263,876. The company has a quick ratio of 1.29, a current ratio of 2.32 and a debt-to-equity ratio of 0.39. The business has a 50-day simple moving average of $233.60 and a two-hundred day simple moving average of $224.39. The firm has a market capitalization of $9.97 billion, a price-to-earnings ratio of 28.14, a price-to-earnings-growth ratio of 2.08 and a beta of 1.11. Teleflex Incorporated has a one year low of $177.63 and a one year high of $276.43.

Teleflex (NYSE:TFX - Get Free Report) last announced its earnings results on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, topping the consensus estimate of $3.26 by $0.12. The company had revenue of $773.90 million for the quarter, compared to analysts' expectations of $769.01 million. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. The business's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.52 earnings per share. As a group, research analysts predict that Teleflex Incorporated will post 13.73 EPS for the current year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.64%. The ex-dividend date of this dividend was Thursday, February 29th. Teleflex's dividend payout ratio (DPR) is 18.06%.

Analyst Ratings Changes

Several analysts recently weighed in on TFX shares. Raymond James increased their target price on Teleflex from $227.00 to $271.00 and gave the company an "outperform" rating in a research note on Wednesday, December 20th. Truist Financial dropped their target price on shares of Teleflex from $270.00 to $265.00 and set a "hold" rating on the stock in a research report on Friday, February 23rd. JMP Securities reiterated a "market outperform" rating and set a $285.00 target price on shares of Teleflex in a research note on Friday, February 23rd. Royal Bank of Canada decreased their price target on shares of Teleflex from $272.00 to $265.00 and set an "outperform" rating on the stock in a research report on Friday, February 23rd. Finally, StockNews.com lowered shares of Teleflex from a "buy" rating to a "hold" rating in a research report on Friday, February 23rd. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $265.56.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.